Vyndamax is a Oral Capsule, Liquid Filled in the Human Prescription Drug category. It is labeled and distributed by Pfizer Laboratories Div Pfizer Inc. The primary component is Tafamidis.
Product ID | 0069-8730_013d062d-5786-4f73-9d50-98476f9b478d |
NDC | 0069-8730 |
Product Type | Human Prescription Drug |
Proprietary Name | Vyndamax |
Generic Name | Tafamidis |
Dosage Form | Capsule, Liquid Filled |
Route of Administration | ORAL |
Marketing Start Date | 2019-05-16 |
Marketing Category | NDA / NDA |
Application Number | NDA212161 |
Labeler Name | Pfizer Laboratories Div Pfizer Inc |
Substance Name | TAFAMIDIS |
Active Ingredient Strength | 61 mg/1 |
NDC Exclude Flag | N |
Listing Certified Through | 2020-12-31 |
Marketing Start Date | 2019-08-27 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | NDA |
Application Number | NDA212161 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | EA |
Marketing Start Date | 2019-08-27 |
Marketing Category | NDA |
Application Number | NDA212161 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | EA |
Marketing Start Date | 2019-08-27 |
Ingredient | Strength |
---|---|
TAFAMIDIS | 61 mg/1 |
SPL SET ID: | 1b4121ee-a733-4456-a917-be2603477839 |
Manufacturer | |
UNII | |
RxNorm Concept Unique ID - RxCUI |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
VYNDAMAX 90474569 not registered Live/Pending |
Wyeth LLC 2021-01-19 |
VYNDAMAX 88369665 not registered Live/Pending |
Wyeth LLC 2019-04-03 |
VYNDAMAX 88248161 not registered Live/Pending |
Wyeth LLC 2019-01-03 |